Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 23Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 3Triple Negative Breast Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Lymphangioma 2Hyperglycemia 2Head and Neck Squamous Cell Cancer 2Vascular Malformations 1Uveal Melanoma 1Stomach Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Meningioma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Hormone Receptor Positive Breast Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Exanthema 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Recurrence × Alpelisib × Clear all
NCT02155088 2021-04-08

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
118 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡